Search: L773:1470 2045 OR L773:1474 5488 > (2015-2019) > Risk of complicatio...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 08107naa a2200697 4500 | |
001 | oai:lup.lub.lu.se:5de20534-367b-403b-899a-d876b06666aa | |
003 | SwePub | |
008 | 190311s2019 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:140416376 | |
024 | 7 | a https://lup.lub.lu.se/record/5de20534-367b-403b-899a-d876b06666aa2 URI |
024 | 7 | a https://doi.org/10.1016/S1470-2045(18)30837-42 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1404163762 URI |
040 | a (SwePub)lud (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Froyman, Wouteru University Hospitals Leuven,Catholic University of Leuven4 aut |
245 | 1 0 | a Risk of complications in patients with conservatively managed ovarian tumours (IOTA5) : a 2-year interim analysis of a multicentre, prospective, cohort study |
264 | 1 | c 2019 |
300 | a 11 s. | |
520 | a Background: Ovarian tumours are usually surgically removed because of the presumed risk of complications. Few large prospective studies on long-term follow-up of adnexal masses exist. We aimed to estimate the cumulative incidence of cyst complications and malignancy during the first 2 years of follow-up after adnexal masses have been classified as benign by use of ultrasonography. Methods: In the international, prospective, cohort International Ovarian Tumor Analysis Phase 5 (IOTA5) study, patients aged 18 years or older with at least one adnexal mass who had been selected for surgery or conservative management after ultrasound assessment were recruited consecutively from 36 cancer and non-cancer centres in 14 countries. Follow-up of patients managed conservatively is ongoing at present. In this 2-year interim analysis, we analysed patients who were selected for conservative management of an adnexal mass judged to be benign on ultrasound on the basis of subjective assessment of ultrasound images. Conservative management included ultrasound and clinical follow-up at intervals of 3 months and 6 months, and then every 12 months thereafter. The main outcomes of this 2-year interim analysis were cumulative incidence of spontaneous resolution of the mass, torsion or cyst rupture, or borderline or invasive malignancy confirmed surgically in patients with a newly diagnosed adnexal mass. IOTA5 is registered with ClinicalTrials.gov, number NCT01698632, and the central Ethics Committee and the Belgian Federal Agency for Medicines and Health Products, number S51375/B32220095331, and is ongoing. Findings: Between Jan 1, 2012, and March 1, 2015, 8519 patients were recruited to IOTA5. 3144 (37%) patients selected for conservative management were eligible for inclusion in our analysis, of whom 221 (7%) had no follow-up data and 336 (11%) were operated on before a planned follow-up scan was done. Of 2587 (82%) patients with follow-up data, 668 (26%) had a mass that was already in follow-up at recruitment, and 1919 (74%) presented with a new mass at recruitment (ie, not already in follow-up in the centre before recruitment). Median follow-up of patients with new masses was 27 months (IQR 14–38). The cumulative incidence of spontaneous resolution within 2 years of follow-up among those with a new mass at recruitment (n=1919) was 20·2% (95% CI 18·4–22·1), and of finding invasive malignancy at surgery was 0·4% (95% CI 0·1–0·6), 0·3% (<0·1–0·5) for a borderline tumour, 0·4% (0·1–0·7) for torsion, and 0·2% (<0·1–0·4) for cyst rupture. Interpretation: Our results suggest that the risk of malignancy and acute complications is low if adnexal masses with benign ultrasound morphology are managed conservatively, which could be of value when counselling patients, and supports conservative management of adnexal masses classified as benign by use of ultrasound. Funding: Research Foundation Flanders, KU Leuven, Swedish Research Council. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Reproduktionsmedicin och gynekologi0 (SwePub)302202 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Obstetrics, Gynaecology and Reproductive Medicine0 (SwePub)302202 hsv//eng |
700 | 1 | a Landolfo, Chiarau Catholic University of Leuven,Queen Charlotte's and Chelsea Hospital4 aut |
700 | 1 | a De Cock, Bavou Catholic University of Leuven4 aut |
700 | 1 | a Wynants, Laureu Catholic University of Leuven4 aut |
700 | 1 | a Sladkevicius, Povilasu Lund University,Lunds universitet,Obstetrisk, gynekologisk och prenatal ultraljudsdiagnostik,Forskargrupper vid Lunds universitet,Obstetric, Gynaecological and Prenatal Ultrasound Research,Lund University Research Groups,Skåne University Hospital4 aut0 (Swepub:lu)obst-psl |
700 | 1 | a Testa, Antonia Carlau Catholic University of the Sacred Heart, Rome,Policlinico Universitario Agostino Gemelli4 aut |
700 | 1 | a Van Holsbeke, Carolineu Hospital Oost-Limburg4 aut |
700 | 1 | a Domali, Ekateriniu Alexandra Hospital, Athens,National and Kapodistrian University of Athens4 aut |
700 | 1 | a Fruscio, Robertu University of Milano-Bicocca,San Gerardo Hospital4 aut |
700 | 1 | a Epstein, Elisabethu Karolinska Institutet,Stockholm South General Hospital4 aut0 (Swepub:lu)obst-eep |
700 | 1 | a dos Santos Bernardo, Maria Joséu Centro Hospitalar Universitário de Lisboa Central4 aut |
700 | 1 | a Franchi, Dorellau European Institute of Oncology4 aut |
700 | 1 | a Kudla, Marek Jerzyu Medical University of Silesia4 aut |
700 | 1 | a Chiappa, Valentinau Istituto Nazionale dei Tumori4 aut |
700 | 1 | a Alcazar, Juan Luisu University Clinic of Navarra4 aut |
700 | 1 | a Leone, Francesco Paolo Giuseppeu University of Milan,Luigi Sacco University Hospital4 aut |
700 | 1 | a Buonomo, Francescau Burlo Garofolo Pediatric Institute4 aut |
700 | 1 | a Hochberg, Lauriu University of South Florida4 aut |
700 | 1 | a Coccia, Maria Elisabettau University of Florence4 aut |
700 | 1 | a Guerriero, Stefanou Azienda Ospedaliero Universitaria-Policlinico Duilio Casula,University of Cagliari4 aut |
700 | 1 | a Deo, Nanditau Whipps Cross University Hospital4 aut |
700 | 1 | a Jokubkiene, Ligitau Lund University,Lunds universitet,Urogynekologi och reproduktionsfarmakologi,Forskargrupper vid Lunds universitet,Urogynaecology and Reproductive Pharmacology,Lund University Research Groups,Skåne University Hospital4 aut0 (Swepub:lu)obst-ljo |
700 | 1 | a Kaijser, Jeroenu Ikazia Hospital4 aut |
700 | 1 | a Coosemans, Anu University Hospitals Leuven,Catholic University of Leuven4 aut |
700 | 1 | a Vergote, Ignaceu University Hospitals Leuven,Catholic University of Leuven4 aut |
700 | 1 | a Verbakel, Jan Yvanu University of Oxford,Catholic University of Leuven4 aut |
700 | 1 | a Bourne, Tomu Queen Charlotte's and Chelsea Hospital,Catholic University of Leuven,University Hospitals Leuven4 aut |
700 | 1 | a Van Calster, Benu Catholic University of Leuven,Leiden University Medical Centre4 aut |
700 | 1 | a Valentin, Lilu Lund University,Lunds universitet,Obstetrisk, gynekologisk och prenatal ultraljudsdiagnostik,Forskargrupper vid Lunds universitet,Obstetric, Gynaecological and Prenatal Ultrasound Research,Lund University Research Groups,Skåne University Hospital4 aut0 (Swepub:lu)obst-lva |
700 | 1 | a Timmerman, Dirku Catholic University of Leuven,University Hospitals Leuven4 aut |
710 | 2 | a University Hospitals Leuvenb Catholic University of Leuven4 org |
773 | 0 | t The Lancet Oncologyg 20:3, s. 448-458q 20:3<448-458x 1470-2045x 1474-5488 |
856 | 4 | u http://dx.doi.org/10.1016/S1470-2045(18)30837-4y FULLTEXT |
856 | 4 8 | u https://lup.lub.lu.se/record/5de20534-367b-403b-899a-d876b06666aa |
856 | 4 8 | u https://doi.org/10.1016/S1470-2045(18)30837-4 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:140416376 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.